Transforming growth factor beta (TGFjO) 
Introduction
Transforming growth factor beta (TGFjO), a recently discovered polypeptide, modulates growth of normal and neoplastic cells. Since little is known concerning in vivo disposition of TGF,#, we performed studies to examine the hepatic processing of biologically active '25I-TGF() in the rat. After intravenous injection, '25I-TGF,& disappeared from the plasma with an initial tI/2 of 2.2 min; partial hepatectomy delayed the plasma disappearance of 1251I-TGFI by 80%. 60 min after intrafemoral injection, 63% of the recovered label was present in liver and/ or bile; by 90 min, most of the label removed by the liver (83%) had been slowly excreted into bile. Nearly all the label in bile (96%) was soluble in trichloracetic acid and not immunoprecipitable by specific antiserum. Colchicine and vinblastine inhibited cumulative biliary excretion of label by 28 and 37%, respectively; chloroquine and leupeptin each increased the amount of label in bile that was precipitable by trichloracetic acid and that coeluted with authentic '25I-TGFB on molecular sieve chromatography. There was efficient first-pass hepatic extraction of 125I-TGFi (36%) in the isolated perfused rat liver, which was inhibited by unlabeled TGFft (but not by epidermal growth factor, EGF) and by lectins in a dose-dependent manner, prolonged fasting also decreased clearance (26%). After fractionation of liver by differential or isopycnic centrifugation, radiolabel codistributed with marker enzymes for lysosomes. The results indicate rapid, extensive, inhibitable, and organselective extraction of TGFjO by the liver. After extraction, TGF,8 undergoes efficient transhepatic transport, extensive intracellular metabolism, and slow but complete biliary excretion of its metabolites. Liver fractionation studies and pharmacologic manipulations suggest that these processes are associated with organelles that include microtubules and lysosomes. The data suggest that the liver is a major target tissue or site of metabolism for biologically active TGFft.
TGFO causes reversible morphologic transformation and growth in soft agar of mesenchymally derived mouse AKR-2B and rat NRK cells (2, 3) . AKR-2B cells are stimulated to divide in monolayer by the addition of TGF/3 but only after a prolonged prereplicative phase compared to other growth factors such as epidermal growth factor (EGF) (4) . Also, TGF(# causes the early induction of c-sis followed by release of platelet derived growth factor (PDGF)-like material and the induction of PDGF-inducible genes (e.g., c-fos c-myc), but with delayed kinetics relative to induction by PDGF (5) . Thus, the mitogenic effect of TGF(# on AKR-2B cells appears to be indirect through the induction ofc-sis and subsequent autocrine stimulation by PDGF-like material. In contrast to its growth stimulatory effects on mesenchymal cells, TGF(# inhibits the monolayer growth of a number of normal epithelial cells, including rat hepatocytes (6) and human keratinocytes (7) , as well as inhibiting the soft agar growth of a number of carcinoma cell lines (8) . In fact, TGF# is similar if not identical to the growth inhibitor isolated by Holley and co-workers from medium conditioned by African green monkey kidney cells (9) . TGF(P appears to be an important regulator of cell proliferation for which many cell types have specific, high affinity, membrane receptors (10).
TGFj3 is ubiquitous; it has been detected in normal liver, lung, kidney, submaxillary gland, brain, placenta and heart tissue, as well as in embryos (1 1, 12) . Platelets have been shown to be a rich source of TGF(P and many laboratories purify TGF(1 from outdated platelets (1) . The molecule is released from cells in a latent, high molecular weight form; activation in vitro can be achieved by extremes of pH (13) and by plasmin, a cell-associated protease (Lyons et al., unpublished observations). Whether this high molecular weight form represents a precursor molecule and/or attachment to a binding protein, and whether in vivo conversion of latent to active form occurs in the plasma or elsewhere is presently unknown.
The gene for TGF1B has been cloned by Derynck and coworkers from a human genomic library and from cDNA libraries derived from human term placenta and the human fibrosarcoma line HT 1080 (14) . It is transcribed into a 2.5-kb mRNA present in a wide variety of normal and transformed cells. Of interest, mRNA for TGF# has not been detected in normal liver (14) . Indeed, the liver may not synthesize TGF3, but may play a role in clearing this polypeptide from the plasma. As there is ample precedent for the hepatic extraction and biliary excretion of a number of circulating macromolecules (15) (16) (17) , including growth-active polypeptides such as EGF (18, 19) , we examined the hepatic processing of TGF,6.
Our results strongly suggest that the liver plays a major role in the clearance and metabolism of biologically active TGFj3.
Methods
Peptides and reagents. TGF6I was purified from human platelets by the method of Assoian et al. (1) with the addition of a final purification step consisting ofreverse phase C-18 high performance liquid chromatography (HPLC) with a 45% to 60% acetonitrile gradient in water with 0.1% trifluoroacetic acid (10) . This platelet-derived TGFj has been shown to be homogeneous on gel electrophoresis under denaturing and reducing conditions (8) .
EGF was purified from adult male mouse submaxillary glands by the method of Savage and Cohen (20) Preparation of radiolabeled compounds. Purified TGF6 was radioiodinated with '25I-labeled Bolton-Hunter reagent from Amersham Corp. (Arlington, IL) as previously described (10) . Biological activity was determined by demonstrating growth-stimulating activity for AKR-2B cells in a soft agar assay and showing competition in a radioreceptor assay using AKR-2B (clone 84A) cells (10) . Specific activity was determined to be -80-100 sCi/Mg.
Purified EGF was iodinated with Nal25l (Amersham Radiochemicals, Arlington Heights, IL) by a modification of the chloramine T reaction (21) . Biologic activity was determined in a mitogenic assay with AKR-2B cells (21) . The labeled EGF had a specific activity of 100-150 MCi//Ag. Experimental models. All experiments were conducted with male Sprague-Dawley rats weighing between 225 and 320 g. For in vivo experiments, we used rats anesthetized with intraperitoneal pentobarbital (40 mg/kg) and prepared with bile fistulae as previously described (22) . In some ofthese experiments, we performed a hepatectomy (70%) or sham operation and took serial blood samples from the femoral artery after administration of the labeled peptide (23) . For in vitro experiments, we used an isolated rat liver model perfused in a nonrecirculating fashion with a nonhemoglobin perfusate as previously described in detail (24). In some ofthese experiments, rats were subjected to prolonged fasting (72 h) before isolation of livers.
To assess the distribution of '25I-TGF# within the liver cell, we performed three types oftissue fractionation studies after homogenization of liver with a Potter-Elveheim homogenizer as previously described (25) . First, to provide an estimate of the amount of label associated with organelles, we prepared a postnuclear supernatant containing both organelles and cell sap (extract or E fraction) by differential centrifugation and subjected it to ultracentrifugation to separate a high-speed pellet (75,000 g X 40 min) or particulate fraction from a supernatant devoid oforganelles. In some ofthese experiments, we added a detergent, Triton X-100 (1% vol:vol), to the E fraction before ultracentrifugation. In a second set of experiments, the E fraction was further separated into four additional fractions by differential centrifugation as described (25) . These fractions were enriched in mitochondria (heavy mitochondrial or M fraction), lysosomes (light mitochondrial or L fraction), endoplasmic reticulum (microsomal or P fraction), and cytosol (final supernatant or S fraction). In a third set of experiments, we performed isopycnic centrifugation of ML fractions on linear sucrose gradients (10 to 60%) as described (25) .
In separate experiments, we mixed lectins, unlabeled TGFII or EGF in the perfusate of isolated livers to provide a steady-state environment to affect the hepatic extraction of the labeled peptide.
In another series of experiments in rats with bile fistulae, we injected colchicine (5 gmol/kg) or vinblastine (10 mg/kg) into the femoral vein 2 h before administration of labeled peptide. The dose of colchicine was similar to that used in assessing the effect ofthis microtubule binding agent on the hepatic transport of IgA (26) , while the dose ofvinblastine was similar to that used in assessing the effect ofthis microtubule binding agent on the biliary excretion of lysosomal enzymes (22) . In those experiments aimed at studying the effects of lysosomotropic agents on the metabolism of '25I-TGF#,, we injected leupeptin (5 mg) or chloroquine (50 mg/kg) intravenously or intraperitoneally, respectively, into rats with bile fistulae 1 h before injection of labeled peptide. These doses were similar to those used by others describing the inhibitory effect ofleupeptin on the hepatic metabolism of asialoglycoproteins (27) and the inhibitory effect of chloroquine on hepatic metabolism of EGF (19) .
Characterization of radiolabel in bile was performed by three separate techniques. TCA precipitation was performed with 2 ml of 10% TCA after addition of 1% BSA to 100 Ml of bile. Immunoprecipitation was performed using a polyclonal antibody directed against native TGFB, which was raised in rabbits (Keski-Oja et al., manuscript in preparation). Antibody-antigen complexes were precipitated with 10% (wt/vol) Staphylococcus A (Pansorbin, Calbiochem) and the precipitated radioactivity analyzed by polyacrylamide gel electrophoresis (PAGE) using 0.1% sodium dodecyl sulfate (SDS) or in a gamma counter. Molecular sieve chromatography was performed on a Sephadex G-50 column (1.0 X 117 cm) with a running buffer of 1.0 M acetic acid, 0.05% Triton X-100, and 0.1% BSA. The void and total column volumes were determined with dextran blue and potassium iodide, respectively.
Counting of tissue, blood, and bile samples for 1251 was done by gamma scintillation. Statistical analyses were done using a two-tailed Student's t test.
Results
Hepatic uptake of '25I-TGF,8. The rate of disappearance of TGF,3 from plasma was studied by injecting '25I-TGF(3 into the rat femoral vein, taking serial samples of blood, and determining the disappearance of label from the plasma. Fig. 1 shows that the plasma disappearance ofradioactivity was rapid after systemic administration of '25I-TGFtB (initial t1/2 of 2.2±0.1 min) and that the disappearance was prolonged nearly twofold (P < 0.03) after 70% hepatectomy (initial t1/2 of 4.0±0.4 min). These determinations were made after a 5-minute equilibration period following hepatectomy.
The uptake of '25I-TGFf3 in various organs was also determined. Fig. 2 shows that 43% of the injected radioactivity was found in liver and bile 60 min after intravenous administration of '25I-TGFfl; this amount was twofold greater than all other organs combined. The hepatic extraction after systemic administration of '25I-TGF# and '25I-EGF was then compared. TGFB radioactivity and 31% ofinjected '25I-EGF radioactivity in all the organs examined. Fig. 4 compares the hepatic extraction (hepatic uptake and biliary excretion) of radioactivity after administration of radiolabeled TGF# and EGF in both the isolated perfused rat liver (IPRL) model and in the intact animal after either intraportal or intrafemoral delivery. Results 
44.8±4. 1%).
Modulation ofhepatic extraction. We determined the effect of fasting on the uptake process in order to provide initial insight into the factors that regulate the hepatic extraction of TGFft. We fasted rats from solid food for 72 h, prepared isolated livers from fasted and nonfasted controls (n = 5), and measured first-pass extraction of '25I-TGF#. A significant decrease (P < 0.03) in first-pass clearance occurred after prolonged fasting, from 35.8±2.4% to 26.4±2.8% of the injected dose.
To assess the specificity of hepatic clearance of 125I-TGF#, we tested the effect of unlabeled TGF,# and of unlabeled EGF on the first-pass extraction of '25I-TGFj# in the IPRL. As TGFft that achieved maximal inhibition in these experiments) had no effect on first-pass hepatic extraction of '25I-TGFf.
Lectins with different carbohydrate specificities were then tested to determine their effects on hepatic extraction ofTGFP (Fig. 5) . Concanavalin A, which binds to mannose residues, yielded first-pass hepatic extractions of 34.9±3.3%, 25.3+2.7%, 24.4+2.3%, 17.7±2.6%, and 13.4±2.3% of the injected dose when premixed into the perfusate at concentrations of 5, 50, 100, 250, and 500 ,ug/ml, respectively. Wheatgerm agglutinin, which binds to N-acetylglucosamine and sialic acid residues, also decreased hepatic extraction. The kinetics ofappearance ofradioactivity from '251I-TGF,6
Concentrations
in bile was examined. Fig. 6 shows that after systemic administration of 1251-TGF,8, the appearance of radioactivity in bile increased rapidly, peaked at 45 min, and gradually declined over 90 min. After 60 min, 20.1±6.4% of the injected radioactivity appears in bile (Fig. 7) . This is significantly greater (P < 0.05) than the cumulative amount of the percentage of injected '25I-EGF, which appears in bile (5.1±0.3%) over the same time (Fig. 7) .
Characterization of 125lfrom TGFj6 in bile. To define the nature of the radiolabel in bile after in vivo administration of '25I-TGF#, we examined bile containing 1251 by TCA precipitation, immunoprecipitation, and molecular sieve chromatography. When bile collected serially after systemic administration of '25I-TGF# was exposed to TCA, a modest amount was TCA-precipitable (27. 7±0.8% at 10 min); this percentage declined rapidly (6.4±0.6% at 25 min) and remained < 4% for the entire 90-min collection period. In contrast, 94.9±0.7% of radioactivity was TCA-precipitable when 125I-TGF,3 was added directly to bile ("spiked" bile) collected from rats (n = 3) to whom '25I-TGF# had not been administered. Only 28 .3±0.5% of radioactivity in spiked bile could be immunoprecipitated using specific polyclonal antiserum to TGF#, possibly due to the specificity and affinity of TGF, antibodies and/or the complex nature of bile. Analysis of immunoprecipitated material after electrophoresis on 7.5-15% polyacrylamide gradient gels containing 0.1% SDS followed by autoradiography demonstrated a single band that migrated identically to '25I-TGFj3 (data not shown). In contrast, we were unable to demonstrate any immunoprecipitable radioactivity in bile collected after systemic administration of 125I-TGFfi. Finally, Fig. 8 shows results of analysis of radioactivity in bile using molecular sieve chromatography. Bile on the hepatic processing of 1251I-TGF(3 was examined. Table I summarizes results of experiments with administration of microtubule binding agents (vinblastine, colchicine) and lysosomotropic agents (chloroquine, leupeptin) to rats with bile fistulae. There was no significant change in hepatic extraction of radioactivity (hepatic uptake and biliary excretion) at 60 min after administration of '25I-TGFfl with both groups of agents.
However, both groups of agents significantly reduced the radioactivity in bile over this same time interval with a corresponding increase in radioactivity remaining within the liver (Table I) . Ofparticular note, pretreatment with chloroquine and, to a lesser extent, leupeptin increased the percentage of radioactivity in bile that was TCA-precipitable (Table I) . Although only 0.4% of radioactivity in bile was immunoprecipitable after pretreatment with chloroquine, this immunoprecipitable material migrated as a single band identical to authentic '25I-TGFfl on SDS-PAGE followed by autoradiography (data not shown). Also, chloroquine pretreatment of rats given 12511
TGF#l systemically altered the elution profile of radioactivity in bile subjected to molecular sieve chromatography (Fig. 8) ; two peaks, one coeluting with intact '25I-TGF,3 near the void volume, and the other eluting near the total volume (representing smaller molecular weight degradation products) became apparent.
Intracellular compartmentalization of '25I-TGFO. We examined the distribution of 125I between a high-speed pellet and a supernatant of homogenized rat liver 20 min after intrafemoral administration of 125I-TGFfl to provide initial insight into the subcellular localization of '25I-TGF# within the liver (Table II) . In these experiments the majority of 1251 was associated with the particulate fraction. After exposure ofthe postnuclear supernatant to Triton X-100, approximately twothirds ofthe radioactivity previously associated with the particulate fraction was released into the supernatant.
To extend our initial studies that suggested the association of '25I-TGFf with specific organelles, we next determined the subcellular distribution pattern of '25I-TGFfi among liver fractions enriched in various organelles which were prepared by differential centrifugation. As shown in Fig. 9 , which compared distribution patterns of 125I and marker enzymes for various organelles, the distribution of l251 in rat liver 20 min after intrafemoral injection of '25I-TGF# was most similar to the distribution of N-acetyl-ft-glucosaminidase, a lysosomal enzyme, and different from the distribution patterns for enzymes associated with other organelles. In Fig. 10 , we plot the distribution of 1251 and marker enzymes for lysosomes and mitochondria after density equilibration in a sucrose gradient of a fraction enriched in these two organelles (i.e., ML fraction) under two circumstances: first, 125I-TGFft was injected into rats 20 min before the preparation of the ML fraction, which was then placed on the gradient; second, '25I-TGF(3 was added directly to the ML fraction prior to placing the fraction on the gradient. When '25I-TGFj# was injected into the rat and extracted by the liver before preparation of the ML fraction, the radioactivity entered the gradient and displayed a distribution pattern similar to those for N-acetyl-ft-glucosaminidase, a lysosomal enzyme, and malate dehydrogenase, a marker enzyme for mitochondria (Fig. 10) . In contrast, when labeled TGFft was added directly to the ML fraction, the radioactivity remained at top of the gradient (Fig. 10) .
Discussion
We have demonstrated that biologically active, 125I-TGFfl is taken up by the liver (36% first-pass hepatic clearance) in a relatively organ-specific manner. This efficient clearance is decreased by fasting and inhibited by lectins and by TGF(# in a concentration-dependent manner; it is not affected by EGF. After extraction, radioactivity is excreted into bile slowly but efficiently, with 80% of the extracted radioactivity present in bile after 90 min; virtually all of the radioactivity in bile is TCA-soluble, not precipitable with specific antiserum to TGF#, and demonstrates an elution profile by gel filtration different from that of authentic '25_-TGF(3. All of these observations suggest extensive metabolism of the peptide. The amount of radioactivity excreted into bile is reduced by microtubule binding and lysosomotropic agents, an observation compatible with vesicular transport. The majority ofthe radioactivity in the liver associates with a particulate fraction and can be released by exposure to a detergent, an observation also compatible with sequestration of label in vesicles. Lysosomes '251-TGFfl was injected into the femoral vein of rats (n = 3) and the liver removed 20 min later. The liver was homogenized and the amount of radioactivity in the supernatant and pellet after ultracentrifugation determined. In separate experiments (n = 3), Triton X-100 was added to the homogenate before centrifugation. Data are mean±SEM.
appear to constitute one subset of vesicles that sequester 1251.
TGFft, as suggested by the findings that lysosomotropic agents inhibit the degradation ofthis molecule during its transhepatic transport and that radioactivity and marker enzymes for lysosomes codistribute after tissue fractionation and differential or isopycnic centrifugation. Overall, we interpret these results as indicating that the liver is the major organ involved in the handling of biologically active TGF,6.
Because the hepatic processing of another growth active polypeptide, EGF, had been extensively studied (18, 19) , we Significant inhibition of biliary excretion of TGF,3 by microtubule binding agents (vinblastine, colchicine) was demonstrated, implying involvement of microtubules and vesicles in the transport and excretory processes. The association of 125I1 TGF,# with a particulate fraction of a liver homogenate after high-speed centrifugation, and the release ofthe label from this fraction after exposure to a detergent, are also compatible with sequestration of 125I-TGF,3 in intracellular vesicles (33) . Lysosomotropic agents (chloroquine, leupeptin) inhibited degradation of '25I-TGF(B, as evidenced by the presence in bile of (a) significantly more TCA-precipitable radioactivity, (b) immunoprecipitable radioactivity, and (c) a peak of radioactivity coeluting with authentic '251I-TGFj3 on molecular sieve chromatography after administration of chloroquine. This observation suggests that lysosomes are one subclass of vesicles involved in the hepatic processing of TGF,#. Additional support for the role of hepatocyte lysosomes in the intracellular metabolism and biliary secretion of TGFB comes from our studies demonstrating codistribution of '25I-TGFB with marker enzymes for lysosomes after differential or isopycnic centrifugation. We have previously described the existence ofa lysosome-to-bile hepatic excretory pathway that may be a final common pathway whereby the hepatocyte disassembles some macromolecules and releases into bile some end-products of partial or complete lysosomal hydrolysis (34) (35) (36) . Based on the data presented here, this pathway would appear to constitute the most likely route for the transhepatic transport and biliary excretion of TGF,. Experimental approaches other than the biochemical one taken in these experiments, such as electron microscopic autoradiography, would be useful in further defining the pathway of transhepatic transport of TGFfl.
The physiological significance of our observations remains to be determined. As suggested earlier, the data are consistent with the liver being either a major target organ and/or a site of metabolism of biologically active TGF,3. TGFP has been shown to inhibit EGF-stimulated DNA synthesis ofnormal rat hepatocytes (6) . It is provocative to attribute control of hepatocyte growth and differentiation to the modulating influences of stimulatory (e.g., EGF) and inhibitory (e.g., TGFj#) growth factors (37) . Also, serum contains detectable amounts of TGF,# (80-200 ng/ml) that is derived from platelets (38) . Current data suggest that the TGFB released by platelets in vivo is in a latent form of higher molecular weight than biologically active TFG,3 (13) . While it is known that this latent form of TGFft can be activated in vitro by extremes of pH (13) and plasmin (Lyons et al., unpublished observations), the mechanism by which latent TGF# is activated in vivo is unclear. One possibility is that activation occurs by proteolytic cleavage either in the plasma compartment or at sites of vascular injury after release of latent TGFB from platelets. Removal of the resulting biologically active form of TGF,# from plasma by efficient hepatic clearance and subsequent lysosomal degradation would then be important to prevent unwanted biological effects of the peptide at distant sites. The data presented here, coupled with information regarding low plasma levels of TGFjO, suggest that the liver may play a major role in regulating levels of circulating, biologically active TGFIO.
